Previous 10 | Next 10 |
Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire – Achieved First Quarter 2022 Net Revenues of $47.7 Million , Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from ...
Karyopharm Therapeutics (NASDAQ:KPTI) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is -$0.62 and the consensus Revenue Estimate is $34.41M (+47.9% Y/Y). Over the last 3 months, EPS estimates have seen 3 upward revisions and ...
AAWW,ABEV,ABUS,ACIW,ADNT,ADT,AGIO,ALDX,ALE,AMCX,AMR,APD,APO,APTV,ARGX,ARW,AUTL,AVEO,BALY,BCE,BCRX,OTCQX:BDRBF,BDX,BERY,BFLY,BLD,BLL,OTC:BLRDF,BUD,BXRX,CAH,CARS,CBRE,CCJ,CCOI,CCRD,CIM,CIO,CMRE,CNCE,CNSL,COMM,COP,CROX,CTHR,CWEN,D,DBRG,DDOG,DEN,DFIN,OTCQX:DLAKF,DLX,DNOW,DTM,OTCQX:EDVMF,ENG,EPAM,...
Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022 PR Newswire -- Conference Call Scheduled for Thursday, May 5, 2022 , at 8:30 a.m. ET -- NEWTON, Mass. , April 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (N...
Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting PR Newswire NEWTON, Mass. , April 27, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical c...
Karyopharm to Participate at the Canaccord Genuity Horizons in Oncology Conference PR Newswire NEWTON, Mass. , April 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer the...
Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appointment of Reshma Rangwala, MD, PhD as Chief Medical Officer PR Newswire - Formerly of Aravive, Genmab and Merck & Co., Dr. Rangwala will Lead Karyo...
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer PR Newswire Study Results to be Presented at the European Society of Medical Oncology's Virtual Plenary and the Societ...
Karyopharm Names New Head of Investor Relations PR Newswire – Elhan Webb , CFA, Formerly of Rubius Therapeutics and Radius Health, Appointed as Senior Vice President of Investor Relations – – Webb Brings More than 20 Years of Divers...
Karyopharm to Participate at the Barclays Global Healthcare Conference PR Newswire NEWTON, Mass. , March 9, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...